---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-032355"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:28:03.565358+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties

## Summary
- MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
- Fulcrum forfeits all future milestone payments (up to $298.5M per target), royalties, and research cost reimbursement.
- Fulcrum had received $10M upfront, $2.5M prepaid research funding, and achieved a $2.5M preclinical milestone.
- Parties will continue obligations until June 26, 2025; no further revenues from the agreement after termination.

## SEC filing metadata
- accession: 0000950170-25-032355
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/0000950170-25-032355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/fulc-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-032355
- JSON: https://secwatch.observer/filing/0000950170-25-032355.json
- Plain text: https://secwatch.observer/filing/0000950170-25-032355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.